Parallax Volatility Advisers, L.P. Sage Therapeutics, Inc. Transaction History

Parallax Volatility Advisers, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $238,420 - $319,592	7,386 New	7,386 $289,000
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $353,438 - $538,902	-6,051 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$41.13 - $62.45 $248,877 - $377,884	6,051 New	6,051 $370,000
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $416,626 - $1.07 Million	-6,923 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $182,236 - $246,758	1,299 Added 23.1%	6,923 $971,000
Q2 2019 Aug 14, 2019	SELL	$157.85 - $183.09 $2.27 Million - $2.63 Million	-14,389 Reduced 71.9%	5,624 $1.03 Million
Q4 2018 Feb 14, 2019	BUY	$81.94 - $139.71 $1.02 Million - $1.73 Million	12,392 Added 162.6%	20,013 $1.92 Million
Q3 2018 Nov 14, 2018	BUY	$138.11 - $169.04 $546,363 - $668,722	3,956 Added 107.94%	7,621 $1.08 Million
Q2 2018 Aug 14, 2018	SELL	$140.36 - $175.76 $719,906 - $901,473	-5,129 Reduced 58.32%	3,665 $574,000
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $462,536 - $584,683	3,040 Added 52.83%	8,794 $1.42 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $349,382 - $962,874	5,754	5,754 $948,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.